Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common life-threatening genetic disorders. It is caused by genetic variants in PKD1 and PKD2, which follow an autosomal dominant inheritance pattern. The proteins encoded by PKD1 and PKD2, namely polycystin-1 and polycystin-2, are integral membrane proteins that form an ion-channel complex responsible for the transport of Ca2+ across the cell membrane. Disruptions in their function lead to imbalances in Ca2+ homeostasis, resulting in increased proliferation of tubular epithelial cells and cyst growth. This results in symetrically enlarged kidneys and impaired renal function, which can progress to end-stage renal failure. Currently, the diagnosis of ADPKD relies on ultrasound examination and the presence of clinical symptoms in the patient. Genetic testing for ADPKD is somewhat challenging due to the high genetic and allelic heterogeneity, the complex structure, and the significant homology of PKD1 with 6 pseudogenes in its vicinity. Next-generation sequencing (NGS) methods are not sufficiently specific to distinguish between variants in the gene and pseudogenes, leading to a high number of false-positive results. In routine diagnostics, a two-step approach is currently used to detect variants in PKD1. The first step involves specific amplification of the functional gene using long-range polymerase chain reaction (LR-PCR), followed by NGS or Sanger sequencing. We aimed to evaluate the reliability of whole-exome sequencing (WES) for use in a routine diagnostics by comparing the results obtained with WES or clinical exome analysis (TSO) to those obtained with the newly introduced two-step approach. We identified 13 pathogenic or likely pathogenic variants using WES/TSO in 29 subjects, of which only 8 were confirmed with the new method. We assumed 100 % reliability of WES for 4 variants indetified in exons 41, 44 and 46, so we did not include them in the confirmation. We identified one new variant with the novel approach that was missed previously with TSO panel. Additionally, sequencing of the exon 1 with WES is not reliable, so in subjects with negative WES result, a confirmation with LR-PCR of exon 1 needs to be performed.
|